Zoi Alexakou
Research Subjects
Research Interests
Zoi Alexakou has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Aikaterini Damianaki
Nephrology Department, Hippokration General Hospital, 11527 Athens, Greece
1 shared publication - Dimitrios Petras
Nephrology Department, Hippokration General Hospital, 11527 Athens, Greece
1 shared publication - Emelina Stambolliu
Nephrology Department, Hippokration General Hospital, 11527 Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 31 May 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 298-311
Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility
Hemoperfusion has been considered a promising adjuvant treatment for chronic diseases and some acute states when specific removal of pathogenic factors from the bloodstream is desired. Over the years, advances in adsorption materials (e.g., new synthetic polymers, biomimetic coating, and matrixes with novel structures) have renewed scientific interest and expanded the potential therapeutic indications of hemoperfusion. There is growing evidence to suggest a prominent place for hemoperfusion as an adjuvant treatment in the setting of sepsis or severe coronavirus disease 2019 and as a therapeutic option for chronic complications associated with accumulated uremic toxins in patients with end-stage renal disease. This literature review will describe the principles, therapeutic perspectives, and the emerging role of hemoperfusion as a complementary therapy for patients with kidney disease.
- 31 May 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 298-311
Open AccessExpanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility
Hemoperfusion has been considered a promising adjuvant treatment for chronic diseases and some acute states when specific removal of pathogenic factors from the bloodstream is desired. Over the years, advances in adsorption materials (e.g., new synthetic polymers, biomimetic coating, and matrixes with novel structures) have renewed scientific interest and expanded the potential therapeutic indications of hemoperfusion. There is growing evidence to suggest a prominent place for hemoperfusion as an adjuvant treatment in the setting of sepsis or severe coronavirus disease 2019 and as a therapeutic option for chronic complications associated with accumulated uremic toxins in patients with end-stage renal disease. This literature review will describe the principles, therapeutic perspectives, and the emerging role of hemoperfusion as a complementary therapy for patients with kidney disease.